Kidney Week

Abstract: SA-PO1107

Deoxycholic Acid and the Risk of Death and Cardiovascular Events among Patients with Advanced CKD

Session Information

• CKD: Epidemiology, Risk Factors, and Prevention - 3
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Gu, Jun Ha, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Jun Ha Gu

• Chonchol, Michel, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Michel Chonchol, MD, FASN

• Hoffman, Cole L., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Cole L. Hoffman

• Miyazaki, Makoto, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Makoto Miyazaki, PhD

• Miyazaki-anzai, Shinobu, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Shinobu Miyazaki-anzai

• Nowak, Kristen L., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Kristen L. Nowak, PhD, MPH

• Jovanovich, Anna, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Anna Jovanovich, MD

Background

Circulating levels of the secondary bile acid, deoxycholic acid (DCA), are elevated in chronic kidney disease (CKD) and may contribute to vascular calcification in CKD patients. Whether circulating DCA levels are associated with death and cardiovascular events (CVE) among advanced chronic kidney disease patients is unknown.

Methods

The Homocysteine Study was a randomized double-blind trial evaluating the effects of high doses of folic acid and B vitamins on all-cause mortality (ACM) and CVE in subjects with advanced CKD and elevated serum homocysteine levels. Fasting serum DCA levels were measured in stored serum samples obtained at 3 months in a cohort of 1,054 patients with mainly stage 4 CKD (mean eGFR 18.1± 6.5 mL/min/1.73m²). The study population was divided into quartiles according to plasma DCA levels. We used Cox proportional-hazards models to examine the association between DCE levels with ACM and a composite of CVE (combining myocardial infarction, stroke, and amputation).

Results

Participants had a mean age of 69±11 years. The median DCA level was 119 [63-232] ng/mL. During a median follow-up of 3.0 years, 445 (42%) patients died from any cause and 210 (20%) had a CVE. Higher DCA levels were not associated with higher risks of death. Compared to the first (lowest) quartile, the HR (95% CI) for death were as follows: second quartile, 0.89 (0.74-1.06); third quartile, 0.98 (0.82-1.18) and fourth quartile, 0.88 (0.73-1.06) after adjustment for potential confounders available in the database. Similar results were obtained when DCA was examined as a continuous variable: 0.97 (0.93-1.02). Compared to the lowest quartile, the two highest quartiles of DCA were also not associated with a significantly elevated risk of CVE (HR 0.98, 95% CI 0.82-1.78) and (HR 0.87, 95%CI 0.73-1.05), respectively after multivariate adjustment.

Conclusion

Among HOST participants, DCA was not associated with death and cardiovascular events in patients with advanced CKD not requiring dialysis.

Funding

• Veterans Affairs Support